Patents by Inventor Mark K. Wedel

Mark K. Wedel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND APPARATUS FOR ADMINISTERING GASES INCLUDING NITRIC OXIDE
    Publication number: 20200368271
    Abstract: A method of modulating oxygen saturation levels can include measuring oxygen saturation levels in a patient, administering inhaled nitric oxide, adjusting the dose of oxygen in real time to a second dose based on the inhaled nitric oxide.
    Type: Application
    Filed: January 27, 2020
    Publication date: November 26, 2020
    Inventors: Kurt A. DASSE, Priscilla C. PETIT, David H. FINE, Mark K. WEDEL
  • METHOD AND APPARATUS FOR ADMINISTERING GASES INCLUDING NITRIC OXIDE TO ADDRESS FIBROSIS
    Publication number: 20170165294
    Abstract: A method of modulating oxygen saturation levels can include measuring oxygen saturation levels in a patient, administering inhaled nitric oxide, adjusting the dose of oxygen in real time to a second dose based on the inhaled nitric oxide.
    Type: Application
    Filed: December 11, 2016
    Publication date: June 15, 2017
    Applicant: GENO LLC
    Inventors: Kurt A. Dasse, Priscilla C. Petit, David H. Fine, Mark K. Wedel
  • METHOD AND APPARATUS FOR ADMINISTERING GASES INCLUDING NITRIC OXIDE
    Publication number: 20170165447
    Abstract: A method of modulating oxygen saturation levels can include measuring oxygen saturation levels in a patient, administering inhaled nitric oxide, adjusting the dose of oxygen in real time to a second dose based on the inhaled nitric oxide.
    Type: Application
    Filed: December 11, 2016
    Publication date: June 15, 2017
    Applicant: GENO LLC
    Inventors: Kurt A. Dasse, Priscilla C. Petit, David H. Fine, Mark K. Wedel
  • METHOD AND APPARATUS FOR SCAVENGING PLASMA FREE HEMOGLOBIN
    Publication number: 20170165293
    Abstract: A method of improving hemodynamics includes identifying a mammal having or at risk of developing a vascular depletion of nitric oxide due to nitric oxide scavenging by oxyhemoglobin, and introducing nitric oxide into the mammal's circulation.
    Type: Application
    Filed: December 11, 2016
    Publication date: June 15, 2017
    Applicant: GENO LLC
    Inventors: Kurt A. Dasse, Priscilla C. Petit, Mark K. Wedel, David H. Fine
  • ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B
    Publication number: 20170096662
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Application
    Filed: May 18, 2016
    Publication date: April 6, 2017
    Applicant: Kastle Therapeutics, LLC
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • Administering antisense oligonucleotides complementary to human apolipoprotein B
    Patent number: 9347061
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: May 24, 2016
    Assignee: Genzyme Corporation
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20150231169
    Abstract: Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5?-GCCCAAGCTOGCATCCOTCA-3?, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 20, 2015
    Inventor: Mark K. Wedel
  • Therapeutic antisense oligonucleotide compositions for the treatment of inflammatory bowel disease
    Patent number: 9050354
    Abstract: Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5?-GCCCAAGCTGGCATCCGTCA-3?, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: June 9, 2015
    Assignee: Atlantic Pharmaceuticals (Holdings) Limited
    Inventor: Mark K. Wedel
  • Compositions and methods for treatment of pouchitis
    Patent number: 8946178
    Abstract: The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 3, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Mark K. Wedel, Phillip B. Miner
  • THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20130090368
    Abstract: Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5?-GCCCAAGCTGGCATCCGTCA-3?, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.
    Type: Application
    Filed: August 7, 2012
    Publication date: April 11, 2013
    Applicant: Atlantic Pharmaceuticals Limited
    Inventor: Mark K. Wedel
  • COMPOSITIONS AND METHODS FOR TREATMENT OF POUCHITIS
    Publication number: 20120270920
    Abstract: The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual
    Type: Application
    Filed: November 17, 2011
    Publication date: October 25, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Mark K. Wedel, Philip B. Miner, JR.
  • Compositions and methods for treatment of pouchitis
    Patent number: 8084432
    Abstract: The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: December 27, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Mark K. Wedel, Philip P. Miner, Jr.
  • ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B
    Publication number: 20100297105
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Application
    Filed: March 24, 2008
    Publication date: November 25, 2010
    Applicant: GENZYME CORPORATION
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20090275631
    Abstract: Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5?-GCCCAAGCTGGCATCCGTCA-3?, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.
    Type: Application
    Filed: December 2, 2005
    Publication date: November 5, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventor: Mark K. Wedel
  • Compositions and methods for treatment of pouchitis
    Publication number: 20040162259
    Abstract: The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Mark K. Wedel, Philip B. Miner